Review decision – September 2018

Decision to move the existing guidance to the static list

We would like to update you on the decision made regarding the review of the existing guidance on TA359; Idelalisib for previously treated chronic lymphocytic leukaemia.

No new evidence was identified that suggests a review of this guidance is necessary.

NICE’s Guidance Executive has decided to proceed with this proposal without consultation.

Consequently TA359 will move to the ‘static list’ of technology appraisals.

Review decision paper

Matrix of stakeholders

This page was last updated: 28 September 2018